Cinpanemab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease. It showed no significant influence on disease progression in a 52-week phase 2 clinical trial. The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness. It was under development by Biogen.
See also List of investigational Parkinson's disease drugs Prasinezumab
References
External links Cinpanemab - AlzForum